 Joyce Lee
Concepts (203)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Diseases, Interstitial | 23 | 2019 | 469 | 4.750 |
Why?
| | Idiopathic Pulmonary Fibrosis | 31 | 2018 | 453 | 4.720 |
Why?
| | Arthritis, Rheumatoid | 10 | 2018 | 994 | 1.400 |
Why?
| | Gastroesophageal Reflux | 4 | 2018 | 239 | 1.250 |
Why?
| | Connective Tissue Diseases | 6 | 2018 | 57 | 0.910 |
Why?
| | Respiratory Aspiration | 3 | 2015 | 33 | 0.870 |
Why?
| | Scleroderma, Systemic | 3 | 2019 | 94 | 0.840 |
Why?
| | Histamine H2 Antagonists | 2 | 2013 | 30 | 0.830 |
Why?
| | Proton Pump Inhibitors | 2 | 2013 | 97 | 0.780 |
Why?
| | Alveolitis, Extrinsic Allergic | 4 | 2017 | 84 | 0.740 |
Why?
| | Vital Capacity | 9 | 2018 | 257 | 0.620 |
Why?
| | Prognosis | 17 | 2017 | 3391 | 0.590 |
Why?
| | Lung | 10 | 2019 | 3588 | 0.580 |
Why?
| | Tomography, X-Ray Computed | 12 | 2019 | 2403 | 0.570 |
Why?
| | Autoimmune Diseases | 3 | 2016 | 397 | 0.530 |
Why?
| | Myositis | 1 | 2016 | 41 | 0.530 |
Why?
| | Severity of Illness Index | 8 | 2018 | 2634 | 0.520 |
Why?
| | Rheumatic Diseases | 1 | 2016 | 49 | 0.510 |
Why?
| | Longitudinal Studies | 8 | 2017 | 2481 | 0.500 |
Why?
| | Quality of Life | 2 | 2017 | 2375 | 0.500 |
Why?
| | Aged | 28 | 2018 | 19373 | 0.480 |
Why?
| | Middle Aged | 29 | 2019 | 27189 | 0.460 |
Why?
| | Patient Education as Topic | 2 | 2016 | 687 | 0.460 |
Why?
| | Precision Medicine | 1 | 2017 | 356 | 0.450 |
Why?
| | Patient Satisfaction | 1 | 2016 | 595 | 0.420 |
Why?
| | Pepsin A | 1 | 2011 | 18 | 0.410 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2015 | 237 | 0.400 |
Why?
| | Comprehensive Health Care | 1 | 2011 | 19 | 0.390 |
Why?
| | Risk Assessment | 6 | 2018 | 3022 | 0.390 |
Why?
| | Fundoplication | 1 | 2011 | 51 | 0.380 |
Why?
| | Dyspnea | 3 | 2017 | 202 | 0.370 |
Why?
| | Male | 36 | 2019 | 56700 | 0.370 |
Why?
| | Lung Transplantation | 6 | 2017 | 245 | 0.360 |
Why?
| | Humans | 51 | 2019 | 117098 | 0.360 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2011 | 600 | 0.350 |
Why?
| | Endotoxins | 1 | 2010 | 208 | 0.350 |
Why?
| | Female | 36 | 2019 | 60672 | 0.340 |
Why?
| | Survival Rate | 8 | 2018 | 1681 | 0.340 |
Why?
| | Respiratory Function Tests | 5 | 2018 | 523 | 0.340 |
Why?
| | Pulmonary Fibrosis | 3 | 2018 | 304 | 0.330 |
Why?
| | Carbon Monoxide | 3 | 2017 | 63 | 0.320 |
Why?
| | Acute Lung Injury | 1 | 2010 | 268 | 0.300 |
Why?
| | Depression | 1 | 2015 | 1137 | 0.290 |
Why?
| | Comorbidity | 5 | 2015 | 1487 | 0.290 |
Why?
| | Disease Progression | 5 | 2018 | 2468 | 0.290 |
Why?
| | Autoantibodies | 2 | 2015 | 1333 | 0.270 |
Why?
| | Predictive Value of Tests | 4 | 2017 | 1836 | 0.270 |
Why?
| | Proportional Hazards Models | 5 | 2017 | 1105 | 0.270 |
Why?
| | Cohort Studies | 7 | 2017 | 5052 | 0.250 |
Why?
| | Forced Expiratory Volume | 2 | 2017 | 517 | 0.240 |
Why?
| | Hypertension, Pulmonary | 1 | 2015 | 1771 | 0.240 |
Why?
| | Endothelium, Vascular | 1 | 2010 | 860 | 0.240 |
Why?
| | Diagnosis, Differential | 4 | 2016 | 1341 | 0.230 |
Why?
| | Case-Control Studies | 5 | 2012 | 3099 | 0.220 |
Why?
| | Prospective Studies | 5 | 2017 | 6391 | 0.200 |
Why?
| | Chronic Disease | 5 | 2017 | 1619 | 0.200 |
Why?
| | Self Care | 2 | 2017 | 355 | 0.200 |
Why?
| | Disease Models, Animal | 1 | 2010 | 3648 | 0.190 |
Why?
| | Kaplan-Meier Estimate | 5 | 2017 | 825 | 0.190 |
Why?
| | Lung Diseases | 2 | 2018 | 693 | 0.180 |
Why?
| | Survival Analysis | 3 | 2012 | 1241 | 0.180 |
Why?
| | Disease Management | 4 | 2018 | 560 | 0.180 |
Why?
| | Phenotype | 4 | 2016 | 2892 | 0.170 |
Why?
| | Spirometry | 2 | 2017 | 258 | 0.170 |
Why?
| | Aged, 80 and over | 6 | 2017 | 6464 | 0.170 |
Why?
| | Wnt-5a Protein | 1 | 2018 | 19 | 0.170 |
Why?
| | Radiography | 2 | 2011 | 843 | 0.160 |
Why?
| | Gain of Function Mutation | 1 | 2018 | 30 | 0.160 |
Why?
| | Idiopathic Interstitial Pneumonias | 2 | 2016 | 41 | 0.160 |
Why?
| | Extracellular Vesicles | 1 | 2018 | 82 | 0.150 |
Why?
| | International Cooperation | 1 | 2017 | 173 | 0.140 |
Why?
| | Retrospective Studies | 9 | 2017 | 12848 | 0.140 |
Why?
| | Mucin-5B | 1 | 2018 | 177 | 0.140 |
Why?
| | Amino Acyl-tRNA Synthetases | 1 | 2016 | 25 | 0.140 |
Why?
| | Women's Health | 1 | 2018 | 270 | 0.140 |
Why?
| | Health Status Indicators | 1 | 2017 | 151 | 0.140 |
Why?
| | Tomography Scanners, X-Ray Computed | 1 | 2015 | 18 | 0.130 |
Why?
| | Risk Factors | 7 | 2018 | 8875 | 0.130 |
Why?
| | Adrenal Cortex Hormones | 2 | 2016 | 508 | 0.130 |
Why?
| | Acute Disease | 3 | 2016 | 916 | 0.130 |
Why?
| | Sarcoidosis | 1 | 2017 | 129 | 0.130 |
Why?
| | Cause of Death | 1 | 2017 | 369 | 0.130 |
Why?
| | Immunosuppressive Agents | 2 | 2016 | 674 | 0.130 |
Why?
| | Sleep Wake Disorders | 1 | 2018 | 234 | 0.130 |
Why?
| | Antibiotic Prophylaxis | 1 | 2016 | 97 | 0.130 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2016 | 121 | 0.120 |
Why?
| | Telomere Shortening | 1 | 2014 | 18 | 0.120 |
Why?
| | Focus Groups | 1 | 2016 | 387 | 0.120 |
Why?
| | Pulmonary Medicine | 1 | 2015 | 85 | 0.120 |
Why?
| | Prevalence | 3 | 2015 | 2300 | 0.120 |
Why?
| | Laparoscopy | 1 | 2018 | 401 | 0.120 |
Why?
| | Interviews as Topic | 1 | 2016 | 592 | 0.120 |
Why?
| | United States | 4 | 2018 | 12385 | 0.110 |
Why?
| | Incidence | 2 | 2017 | 2378 | 0.110 |
Why?
| | Interleukin-13 | 1 | 2014 | 134 | 0.110 |
Why?
| | Bronchodilator Agents | 1 | 2015 | 249 | 0.110 |
Why?
| | Counseling | 1 | 2016 | 342 | 0.110 |
Why?
| | Diagnostic Imaging | 1 | 2016 | 294 | 0.110 |
Why?
| | Follow-Up Studies | 3 | 2017 | 4507 | 0.110 |
Why?
| | Telomerase | 1 | 2015 | 207 | 0.110 |
Why?
| | Keratin-18 | 1 | 2012 | 11 | 0.110 |
Why?
| | Sex Factors | 2 | 2018 | 1758 | 0.110 |
Why?
| | Autoimmunity | 2 | 2015 | 829 | 0.110 |
Why?
| | Biopsy | 4 | 2018 | 1056 | 0.110 |
Why?
| | Fatigue | 1 | 2014 | 288 | 0.110 |
Why?
| | Emphysema | 1 | 2013 | 123 | 0.100 |
Why?
| | Algorithms | 2 | 2016 | 1505 | 0.100 |
Why?
| | Epithelial Cells | 2 | 2014 | 940 | 0.100 |
Why?
| | Qualitative Research | 1 | 2016 | 965 | 0.100 |
Why?
| | Biomarkers | 3 | 2016 | 3551 | 0.090 |
Why?
| | Goals | 1 | 2011 | 161 | 0.090 |
Why?
| | Sodium-Potassium-Exchanging ATPase | 1 | 2010 | 47 | 0.090 |
Why?
| | Pulmonary Diffusing Capacity | 3 | 2016 | 58 | 0.090 |
Why?
| | Age Factors | 2 | 2014 | 2951 | 0.090 |
Why?
| | Alveolar Epithelial Cells | 1 | 2010 | 101 | 0.080 |
Why?
| | Health Status | 1 | 2014 | 726 | 0.080 |
Why?
| | Sensitivity and Specificity | 1 | 2013 | 1740 | 0.080 |
Why?
| | Virus Diseases | 1 | 2011 | 201 | 0.080 |
Why?
| | Models, Statistical | 1 | 2012 | 627 | 0.080 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2010 | 406 | 0.080 |
Why?
| | Antibodies, Monoclonal | 1 | 2014 | 1271 | 0.080 |
Why?
| | DNA | 1 | 2014 | 1372 | 0.070 |
Why?
| | Time Factors | 1 | 2017 | 6240 | 0.070 |
Why?
| | Treatment Outcome | 3 | 2018 | 9265 | 0.070 |
Why?
| | Cell Membrane | 1 | 2010 | 681 | 0.070 |
Why?
| | Internationality | 2 | 2017 | 149 | 0.070 |
Why?
| | Signal Transduction | 1 | 2018 | 4606 | 0.070 |
Why?
| | Palliative Care | 1 | 2011 | 623 | 0.060 |
Why?
| | Mutation | 1 | 2015 | 3420 | 0.060 |
Why?
| | Adult | 7 | 2018 | 31014 | 0.060 |
Why?
| | Animals | 4 | 2014 | 32741 | 0.050 |
Why?
| | Mice, Inbred C57BL | 1 | 2010 | 4841 | 0.050 |
Why?
| | Insulin | 1 | 2010 | 2135 | 0.040 |
Why?
| | Intention to Treat Analysis | 1 | 2018 | 69 | 0.040 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 1 | 2018 | 101 | 0.040 |
Why?
| | Mice | 2 | 2014 | 15311 | 0.040 |
Why?
| | Behavior | 1 | 2018 | 92 | 0.040 |
Why?
| | Education | 1 | 2018 | 101 | 0.040 |
Why?
| | Morbidity | 1 | 2018 | 283 | 0.040 |
Why?
| | Sleep Apnea Syndromes | 1 | 2018 | 80 | 0.040 |
Why?
| | Comprehension | 1 | 2018 | 158 | 0.040 |
Why?
| | Antibodies, Antinuclear | 1 | 2016 | 56 | 0.030 |
Why?
| | Linear Models | 1 | 2019 | 802 | 0.030 |
Why?
| | Global Health | 1 | 2018 | 302 | 0.030 |
Why?
| | Mycophenolic Acid | 1 | 2016 | 79 | 0.030 |
Why?
| | California | 1 | 2017 | 366 | 0.030 |
Why?
| | Odds Ratio | 1 | 2018 | 981 | 0.030 |
Why?
| | Evaluation Studies as Topic | 1 | 2015 | 174 | 0.030 |
Why?
| | Pneumonia, Aspiration | 1 | 2015 | 15 | 0.030 |
Why?
| | Monitoring, Physiologic | 1 | 2017 | 257 | 0.030 |
Why?
| | Bronchiolitis Obliterans | 1 | 2015 | 63 | 0.030 |
Why?
| | Age Distribution | 1 | 2015 | 340 | 0.030 |
Why?
| | Regression Analysis | 1 | 2017 | 971 | 0.030 |
Why?
| | Sex Distribution | 1 | 2015 | 331 | 0.030 |
Why?
| | Europe | 1 | 2015 | 349 | 0.030 |
Why?
| | Chicago | 1 | 2014 | 45 | 0.030 |
Why?
| | San Francisco | 1 | 2014 | 55 | 0.030 |
Why?
| | Syndrome | 1 | 2015 | 339 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2018 | 1141 | 0.030 |
Why?
| | Patient Acuity | 1 | 2013 | 42 | 0.030 |
Why?
| | Texas | 1 | 2014 | 188 | 0.030 |
Why?
| | Observational Studies as Topic | 1 | 2013 | 90 | 0.030 |
Why?
| | Mice, SCID | 1 | 2014 | 328 | 0.030 |
Why?
| | Genotype | 1 | 2018 | 1854 | 0.030 |
Why?
| | Enzyme Inhibitors | 1 | 2016 | 775 | 0.030 |
Why?
| | Leukocytes | 1 | 2014 | 280 | 0.030 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2012 | 96 | 0.030 |
Why?
| | Graft Rejection | 1 | 2015 | 536 | 0.020 |
Why?
| | Societies, Medical | 1 | 2015 | 684 | 0.020 |
Why?
| | Torque teno virus | 1 | 2011 | 1 | 0.020 |
Why?
| | Molecular Targeted Therapy | 1 | 2014 | 354 | 0.020 |
Why?
| | DNA Virus Infections | 1 | 2011 | 4 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2018 | 3956 | 0.020 |
Why?
| | Microarray Analysis | 1 | 2011 | 119 | 0.020 |
Why?
| | Up-Regulation | 1 | 2014 | 837 | 0.020 |
Why?
| | Subcellular Fractions | 1 | 2010 | 80 | 0.020 |
Why?
| | Models, Theoretical | 1 | 2014 | 534 | 0.020 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 1114 | 0.020 |
Why?
| | Body Fluids | 1 | 2010 | 60 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1403 | 0.020 |
Why?
| | Pulmonary Alveoli | 1 | 2012 | 373 | 0.020 |
Why?
| | GTPase-Activating Proteins | 1 | 2010 | 71 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2018 | 2227 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2017 | 2831 | 0.020 |
Why?
| | rab GTP-Binding Proteins | 1 | 2010 | 64 | 0.020 |
Why?
| | Telemedicine | 1 | 2017 | 669 | 0.020 |
Why?
| | Prednisone | 1 | 2009 | 233 | 0.020 |
Why?
| | Models, Biological | 1 | 2016 | 1689 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2011 | 761 | 0.020 |
Why?
| | Methotrexate | 1 | 2009 | 229 | 0.020 |
Why?
| | Protein Transport | 1 | 2010 | 402 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2010 | 332 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2011 | 1001 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2011 | 741 | 0.020 |
Why?
| | Antirheumatic Agents | 1 | 2009 | 255 | 0.020 |
Why?
| | Cattle | 1 | 2010 | 957 | 0.020 |
Why?
| | Respiratory Tract Infections | 1 | 2011 | 328 | 0.020 |
Why?
| | Logistic Models | 1 | 2012 | 1877 | 0.020 |
Why?
| | Asthma | 1 | 2018 | 2156 | 0.020 |
Why?
| | Smoking | 1 | 2012 | 1457 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2010 | 2321 | 0.020 |
Why?
| | Apoptosis | 1 | 2012 | 2433 | 0.010 |
Why?
| | Rats | 1 | 2010 | 5172 | 0.010 |
Why?
|
|
Lee's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|